<DOC>
	<DOCNO>NCT01954095</DOCNO>
	<brief_summary>The purpose study analyze body handle respond progesterone treatment parous nulliparous woman risk pre-term birth .</brief_summary>
	<brief_title>The Impact Vaginal IM Progestins Cervix</brief_title>
	<detailed_description>17-hydroxyprogesterone caproate ( 17-OHPC ) recently show reduce rate recurrent preterm birth intravaginal progesterone show reduce rate preterm birth woman short cervix . While intervention reduce rate preterm birth , mechanisms action medication unknown . The objective study collect analyze blood cervicovaginal fluid pregnant woman receive medication intervention cerclage , pessary , NSAIDs , combination thereof . The goal analyse assess impact intervention cervical proteome , cervical cytokine cervical structure identify potential biomarkers response non-response thus provide insight mechanisms action drug .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Inclusion Criteria All Groups Singleton gestation ( 16 0/7 23 6/7 week gestation ) Willing provide inform consent Age 18 50 year inclusive Additionally , Group 1 : One prior term birth ( &gt; 37 0/7 week ) ; No prior spontaneous birth 16 0/7 36 6/7 week ; normal cervical length ( &gt; 25 mm ) Group 2 : Cervical length 20 mm less 16 0/7 23 6/7 week Groups 3 4 : History prior spontaneous birth 16 0/7 34 0/7 week normal cervical length ( &gt; 25mm ) enrollment . Exclusion Criteria All Groups Active labor Active bleeding On progestin therapy , chronic steroid , current NSAID therapy Actively receive study treatment another clinical trial ( observational trial allow ) Major fetal malformation lethal anomaly , anomaly may lead early delivery increase risk neonatal death e.g. , gastroschisis , spina bifida , serious karyotypic abnormality Amniotic membrane prolapse beyond external o ( ostium uterus ) protrude vagina Pregnancy without viable fetus Prenatal care delivery plan elsewhere ( unless study visit make schedule complete outcome information obtain ) Additionally : Group 1 : Cervical dilation great equal 3cm Group 2 : Prior preterm birth ( 16 0/7 34 0/7 ) ; active deep vein thrombosis , pulmonary embolism , history condition ; know liver dysfunction disease ( active hepatitis , HIV ) Group 3 : inability unwillingness use 17OHPC compound product similar composition FDAapproved product ; allergy 17OHPC component Groups 1 , 3 , 4 : cerclage place anticipate ; congenital mullerian abnormality uterus ; positive bacterial vaginosis , chlamydia , gonorrhea , trichomonas Groups 3 4 : current history thrombosis thromboembolic disorder ; know suspect breast cancer , hormonesensitive cancer , history condition ; undiagnosed abnormal vaginal bleeding unrelated pregnancy ; cholestatic jaundice pregnancy , liver tumor , benign malignant , active liver disease ; uncontrolled hypertension</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>17-OHPC , Prometrium , Cerclage , Pre-term birth , Short cervix</keyword>
</DOC>